Rating Rationale
April 28, 2021 | Mumbai
Micro Labs Limited
Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities RatedRs.430 Crore
Long Term RatingCRISIL AA-/Stable (Reaffirmed)
Short Term RatingCRISIL A1+ (Reaffirmed)
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its CRISIL AA-/Stable/CRISIL A1+’ ratings on the bank loan facilities of Micro Labs Limited (Micro Labs).

 

Operating income improved by 5% to Rs. 3850 crores in fiscal 2021, backed by healthy growth in the exports market. Export sales grew by about 35% year-on-year in fiscal 2021, with US being the largest contributor. However, domestic sales growth was moderate at 5% in fiscal 2021, due to lower prescription based sales amidst the pandemic. Operating profitability improved to 21% in fiscal 2021 as compared to 17% a year ago, mainly due to healthy growth in high margin export business, and lower marketing and travelling costs amidst the pandemic. The operating income growth is expected to remain healthy over the medium term, backed by steady growth in the domestic market and sustained increase in exports. Operating profitability is expected to sustain 19-20% on account of steady growth in high-margin exports.

 

Micro Labs has sold 74% stake in its subsidiary, RA Chem India Pvt Ltd (RA Chem) to PE fund Advent international (Advent) for about Rs. 770 crs in October 2020. The funds have been used partly for debt reduction, meeting working capital requirement and remaining in liquid surplus. Consequently, the company’s gearing improved to 0.23 times as on March 31, 2021 from 0.5 times a year ago. Working capital requirement is expected to remain large on account of substantial inventory and export receivables. The company plans capital expenditure (capex) of Rs 350 crore for setting up an active pharmaceutical ingredient (API) unit in Bengaluru over two years. The capex and acquisition, if any, is expected to be funded from internal accruals and liquid surplus, thereby sustaining its healthy capital structure. Gearing is expected to remain below 0.3 times and debt protection metrics is expected to remain comfortable over the medium term. Any higher than expected debt-funded capex or acquisition, or increase in investment in unrelated businesses could impact the company’s financial risk profile and will remain the key monitorables.

 

The ratings continue to reflect Micro Labs’ established position in the domestic formulations market, diversified revenues across therapeutic segments and geographies, and healthy financial risk profile backed by healthy cash accrual and strong liquidity. These strengths are partially offset by susceptibility to intense competition and regulatory changes, working capital-intensive operations, and exposure to investment in unrelated financing business.

Analytical Approach

CRISIL Ratings has combined the business and financial risk profiles of Micro Labs and its subsidiaries because of their significant operational and financial linkages. The entities are collectively referred to as Micro Labs.

 

CRISIL Ratings has adjusted the loans and advances towards unrelated businesses from the networth.

 

Please refer Annexure: List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description

Strengths

  • Established position in the domestic formulations segment: Micro Labs is ranked 19th in the domestic formulations market as per All India Organisation of Chemists and Druggists -AWACS (July 2019). It has a market share of around 2% based on domestic sales. The company is among the top five players in the liver-therapy and oral anti-diabetic segments, and ranks 11th in the cardio vascular products division. It has an established market position in therapies such as anti-diabetes, pain management, ophthalmology, and central nervous system and will focus on other chronic and sub-chronic therapies to drive growth.

 

  • Diversified revenue across therapeutic segments and geographies: The domestic market accounted for about 50% of revenue in fiscal 2021. Micro Labs is present in all therapeutic segments, except oncology and respiratory. The chronic care segment accounts for around 60% of domestic revenue, and anti-bacterials, diabetes and anti-hypertensives for 40%. The share of exports, which stood at about 50% in fiscal 2021, is expected to increase gradually driven by higher growth in regulated markets and institutional sales. To offset any adverse impact of regulatory changes and ensure sustained revenue growth, Micro Labs aims to maintain a balanced portfolio between chronic and acute drugs.

 

  • Healthy financial risk profile: The financial risk profile is driven by a strong networth, and comfortable gearing and debt protection metrics. Networth is estimated to remain strong at Rs 3,100 crore as on March 31, 2021, and grow further with healthy internal accruals. Micro Labs utilised funds from majority stake sale in RA Chem for debt reduction, consequently gearing improved to 0.23 times as on March 31, 2021 from 0.5 times a year ago. Net cash accrual to total debt and interest coverage ratios are healthy, estimated at 1.51 times and 27 times, respectively, for fiscal 2021. Gearing is expected to remain below 0.3 times and debt protection metrics is expected to remain comfortable over the medium term. Any further investment in unrelated financing business could impact the capital structure and will remain the key monitorable.

 

Weaknesses

  • Susceptibility to intense competition and regulatory changes: Despite its established presence in the acute segment (40% revenue in fiscal 2021), intense competition constrains the company’s pricing power in the domestic market. Of late, the domestic pharmaceutical sector has also been subject to increased regulatory scrutiny. About 15% of the products of Micro Labs are under the ambit of the drug price control order (DPCO), but a diversified product profile (the top five brands accounted for less than 20% of the revenue in fiscal 2021), which includes products priced below the ceiling, has improved revenue generation, and should continue to help mitigate the DPCO impact.

 

The company has to comply with regulations in its export destinations. In September 2014, the US Food and Drug Administration issued an import alert letter to Micro Labs for violation of current Good Manufacturing Practices (cGMP) at the Goa plant. While the impact was minimal as the US accounted for less than 5% of the company’s revenue and the issue was resolved post re-inspection of the plant in March 2017, the company remains susceptible to regulatory risk.

 

  • Working capital-intensive operations: Micro Labs is estimated to have large gross current assets of 260 days as on March 31, 2021, on account of large inventory and export receivables. It operates in multiple geographies and has a wide product portfolio and has to maintain substantial inventory to ensure adequate supply. Given its steadily expanding product portfolio and increasing export sales, operations will remain working capital intensive.

 

  • Exposure to unrelated businesses: Micro Labs started investing in real estate in fiscal 2009 through wholly owned subsidiaries, some of which are involved in projects approved by the Slum Rehabilitation Authority (SRA) in Mumbai. Direct exposure includes loans to a few developers. Total direct investments in the unrelated financing business is at Rs 1,035 crore as on March 31, 2020. The company has not received interest on some of the loans and advances because of a slump in the real estate sector. While the company plans to demerge the financing business going forward, any significant increase in investments in unrelated businesses in the interim may impact the company's financial risk profile, and hence, is a key rating sensitivity factor.

Liquidity: Strong

Liquidity is strong, backed by healthy net cash accrual of over Rs. 800 crores annually against debt repayment obligation of Rs 55-95 crores. Cash and cash equivalents is strong at about Rs 770 crore as on March 31, 2021, mainly due to majority stake sale in RA Chem in fiscal 2021. Micro Labs may use part of this liquidity for funding capex plans of Rs. 350 crores over the medium term and acquisitions; however it is expected to maintain atleast Rs. 250-300 crores liquidity on an ongoing basis. Bank limit utilisation averaged 51% over the 12 months through December 31, 2020.

Outlook: Stable

CRISIL Ratings believes Micro Labs will maintain its diversified revenue profile across geographies and its healthy cash accrual over the medium term. The financial risk profile should remain healthy, with strong networth, low gearing, and no major debt-funded capex plan.

Rating Sensitivity Factors

Upward Factors

  • Sustained annual revenue growth of 15%, mainly driven by exports
  • Sustained operating profitability above 20%, led by improved revenue profile
  • Improvement in credit metrics, primarily related to leverage, driven by demerger of unrelated business or substantial reduction in exposure to unrelated businesses

 

Downward Factors

  • Material decline in revenue growth or operating profitability falling below 15% due to regulatory issues or increased competition
  • Substantial weakening in the capital structure, on large, debt-funded capex or acquisitions or increasing investment in unrelated businesses
  • Weakening of financial risk profile because of increase in exposure to unrelated businesses to over Rs. 1,500 crores

About the Company

Micro Labs was set up in 1973 by the late Mr. G C Surana and is now managed by his sons, Mr Dilip Surana and Mr Anand Surana. The company manufactures and distributes pharmaceutical formulations in India and abroad and has presence in more than 60 countries. It has 13 production plants in India.

Key Financial Indicators*

Particulars

Unit

2020

2019

Operating income

Rs.Crore

4126

3774

Adjusted profit after tax (PAT)

Rs.Crore

612

319

Adjusted PAT margin

%

14.5

8.2%

Adjusted debt/adjusted networth

Times

0.51

0.54

Adjusted interest coverage

Times

17.38

13.01

    *Figures with RA Chem consolidated

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon rate (%)

Maturity date

Issue size (Rs.Crore)

Complexity levels

Rating assigned with outlook

NA

Cash Credit*

NA

NA

NA

210.00

NA

CRISIL AA-/Stable

NA

Packing Credit

NA

NA

NA

220.00

NA

CRISIL A1+

*Fully interchangeable with packing credit

Annexure – List of entities consolidated

Names of entities consolidated

Extent of consolidation

Subsidiary/Associate

Brown & Burk UK Ltd

Full

Subsidiary

Micro Labs GMBH

Full

Subsidiary

Micro Labs USA Inc

Full

Subsidiary

Micro Nova Pharmaceutical Industries Ltd, Nigeria

Full

Subsidiary

Micro Labs Pty Ltd

Full

Subsidiary

Brown & Burk AB (wholly owned subsidiary of Brown & Burk UK Ltd)

Full

Subsidiary

Micro Labs Holdings FZE

Full

Subsidiary

Microsynergy Pharmaceuticals FZCO (subsidiary of Micro Labs Holdings FZE)

Full

Subsidiary

Laxmi RA Holdings & Investments Pvt Ltd*

Full

Subsidiary

Indu Pharma Pvt Ltd (subsidiary of RA Chem Pvt Ltd)*

Full

Subsidiary

India SME Investment LLP

Moderate

Associate

Manne Laboratories Pvt Ltd*

Full

Subsidiary

Stern Chempharm LLLP

Moderate

Associate

RA Chem Pharma Limited (Along with Laxmi RA Holdings & Investments Limited)*

Full

Subsidiary

*Applicable till October 2020

Annexure - Rating History for last 3 Years
  Current 2021 (History) 2020  2019  2018  Start of 2018
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT/ST 430.0 CRISIL A1+ / CRISIL AA-/Stable   -- 08-01-20 CRISIL A1+ / CRISIL AA-/Stable   -- 31-10-18 CRISIL AA-/Positive / CRISIL A1+ CRISIL AA-/Positive / CRISIL A1+
All amounts are in Rs.Cr.
 
 
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Cash Credit* 210 CRISIL AA-/Stable Cash Credit* 210 CRISIL AA-/Stable
Packing Credit 220 CRISIL A1+ Packing Credit 220 CRISIL A1+
Total 430 - Total 430 -
*Fully interchangeable with packing credit
Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for Consolidation
CRISILs Bank Loan Ratings

Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
 naireen.ahmed@crisil.com

Anuj Sethi
Senior Director
CRISIL Ratings Limited
B:+91 44 6656 3100
anuj.sethi@crisil.com


Sameer Charania
Director
CRISIL Ratings Limited
D:+91 22 4097 8025
sameer.charania@crisil.com


Aashna Aggarwal
Senior Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
Aashna.Aggarwal@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Ratings Limited

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ("CRISIL Ratings") is a wholly-owned subsidiary of CRISIL Limited ("CRISIL"). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisil.com/ratings 




About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale (each a "Report") that is provided by CRISIL Ratings Limited  (hereinafter referred to as "CRISIL Ratings") . For the avoidance of doubt, the term "Report" includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. Rating by CRISIL Ratings contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way. CRISIL Ratings or its associates may have other commercial transactions with the company/entity.

Neither CRISIL Ratings nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, "CRISIL Ratings Parties") guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Ratings Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL RATINGS' PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL Rating's public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: http://www.crisil.com/ratings/highlightedpolicy.html

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL Ratings you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings Limited is a wholly owned subsidiary of CRISIL Limited.

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011 to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratiings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: www.crisil.com/ratings/credit-rating-scale.html